Sleeve Gastrectomy

How Sleeve Gastrectomy Works

The procedure has two distinct mechanisms. The first is restriction. Sleeve gastrectomy reduces the stomach to roughly 15 to 20 percent of its original volume. That limits how much food can be eaten before the stomach signals fullness. The new shape is narrow and tubular. It fills quickly and empties more slowly than a normal stomach, which extends the feeling of satiety after meals.

The second mechanism is hormonal. The removed portion of the stomach is the fundus and most of the greater curvature — the tissue where the body produces most of its ghrelin. Ghrelin is the hunger hormone. Its levels rise before meals and fall after eating. In obesity, ghrelin is chronically elevated, which drives persistent hunger even when caloric needs are met. When the fundus is removed, that ghrelin-producing tissue is gone permanently. Patients consistently report a significant reduction in hunger in the weeks and months after surgery. This is not willpower — the hormonal drive to eat is genuinely lower.

That hormonal component is what distinguishes sleeve gastrectomy from purely mechanical restriction. A gastric band limits intake but does not change appetite signaling. Sleeve gastrectomy does both. That said, sleeve does not alter how nutrients are absorbed. The small intestine is untouched. Food moves through the digestive tract normally after surgery. Unlike gastric bypass or SADI-S, there is no intestinal rerouting.

The Surgical Procedure

We perform sleeve gastrectomy using the Da Vinci robotic system. The procedure takes about 30 to 50 minutes in our hands. All incisions are small — typically five or six ports through which the robotic instruments and camera are placed. There are no large abdominal incisions.

The operation divides and removes the outer portion of the stomach using a surgical stapler fired along a sizing guide called a bougie. The staple line runs from the lower antrum near the pylorus up to the gastroesophageal junction. The removed portion is extracted through one of the port sites. What remains is a narrow, tube-shaped stomach. The pyloric valve is preserved, so food moves from the stomach into the small intestine in a normal, controlled way. This avoids the dumping syndrome that can occur with procedures that bypass the pylorus.

Robotic technique changes the precision of this operation in a clinically meaningful way. Staple line quality and sleeve angle both affect long-term outcomes — including reflux risk and weight loss durability. With the robotic platform, we have greater range of motion at the instrument tip and improved visualization. Staple line placement is more consistent than with standard laparoscopic technique. My experience as a Da Vinci national proctor is directly relevant here. I perform this procedure frequently and teach it to other surgeons. That level of volume matters to outcomes.

Who Is a Good Candidate for Sleeve Gastrectomy

Candidacy follows the 2022 ASMBS/IFSO guidelines. Surgery is recommended for patients with a BMI of 35 or higher. It should also be considered for patients with a BMI of 30 to 34.9 who have significant weight-related health conditions — type 2 diabetes, hypertension, and obstructive sleep apnea all qualify. The prior threshold of BMI 40 as the entry point without other conditions has been revised. The evidence now supports surgery at lower BMI thresholds when the metabolic burden warrants it.

Sleeve is particularly well-suited to patients who need substantial weight loss but are not good candidates for a procedure that alters nutrient absorption. Patients with Crohn's disease, for example, are generally not good candidates for gastric bypass or a duodenal switch — those procedures involve the small intestine, already a source of complications in Crohn's. Sleeve stays within the stomach only. Patients with multiple prior abdominal surgeries may have adhesions that make bypass anatomy more difficult. In those situations, sleeve is often the more straightforward choice.

For most patients with a BMI in the 35 to 45 range and no severe uncontrolled type 2 diabetes, sleeve produces meaningful, durable weight loss. We discuss the full range of options at every consultation. If you want to understand how procedures compare before that conversation, our procedure comparison page covers this in detail.

Who Sleeve Gastrectomy Is NOT Right For

This section matters as much as the candidacy section above. Sleeve gastrectomy is the wrong procedure for a meaningful portion of patients who come in requesting it.

The most important contraindication is significant gastroesophageal reflux disease (GERD). Sleeve gastrectomy consistently worsens acid reflux in a substantial number of patients. The mechanism is anatomical: the sleeve reduces the angle of His — the natural anti-reflux valve at the gastroesophageal junction — decreases pressure at the lower esophageal sphincter, and increases pressure inside the remaining stomach. Acid moves upward more readily than before surgery. A 2025 systematic review and meta-analysis in Clinical Gastroenterology and Hepatology (Chandan et al.) found that GERD symptom rates nearly triple after sleeve — from about 15 percent before surgery to 48 percent afterward. De novo Barrett's esophagus developed in 5.6 percent of patients pooled across studies. In studies with 10 or more years of follow-up, that rate rose to 11.6 percent. These are not rare outcomes. They are expected outcomes in a meaningful percentage of sleeve patients.

Patients with documented GERD, confirmed esophagitis, Barrett's esophagus, intractable reflux, or gastroparesis should not have a sleeve. The right procedure for those patients is Roux-en-Y gastric bypass. Bypass resolves reflux in the majority of patients rather than worsening it. The gastric pouch in bypass is small and produces very little acid. Bile — a major contributor to reflux-related esophageal damage — is diverted away from the esophagus by the Roux limb. Bypass and sleeve have opposite effects on reflux. That distinction is the most consequential procedure-selection decision we make in bariatric surgery.

The second scenario where sleeve is not the best choice is very high BMI or severe metabolic disease. Patients with BMI above 50, and those with poorly controlled type 2 diabetes, often need more than restriction to reach their metabolic goals. Sleeve does not alter how nutrients are absorbed. For patients who need a stronger metabolic effect, SADI-S or bypass deserves a serious conversation. Dr. Brown is a national proctor for SADI-S and performs it frequently. When that procedure is the better fit, we say so.

Expected Outcomes

At one year after sleeve gastrectomy, most patients lose 50 to 60 percent of their excess weight. A systematic review of more than 5,000 patients found a mean excess weight loss of about 67 percent at one year. The range across studies reflects real variation — starting weight, behavior, follow-up, and surgical technique all influence results.

The SLEEVEPASS trial is the largest randomized trial comparing sleeve gastrectomy and gastric bypass with long-term follow-up. It reported 10-year outcomes in 2022 (Salminen et al., JAMA Surgery). At 10 years, median excess weight loss was 43.5 percent after sleeve and 50.7 percent after bypass. Both procedures produced significant, durable weight loss. Bypass produced slightly better long-term results, and the difference became more apparent at 10 years than at 5. Hypertension remission was superior after bypass. Esophagitis was more common after sleeve. There was no significant difference in type 2 diabetes remission, sleep apnea improvement, or quality of life between the two procedures at 10 years.

The metabolic effects of sleeve gastrectomy extend beyond weight loss. Type 2 diabetes remission rates after sleeve range from 60 to 80 percent in published meta-analyses. Hypertension resolves or significantly improves in about two thirds of patients at one year. Obstructive sleep apnea improves in the large majority of patients who have it. For patients with severe or long-standing diabetes, the evidence shows that malabsorptive procedures produce more complete, more durable metabolic remission than sleeve alone. That conversation belongs at your consultation.

Some patients experience weight regain after 2 to 3 years as the stomach stretches and ghrelin levels partially recover. Revision to bypass or SADI-S is an option when that happens. You can read more on our page covering whether weight loss surgery always works.

Recovery

Most patients stay in the hospital one to two nights after sleeve gastrectomy. The first 24 hours focus on pain management, hydration, and confirming the staple line is intact. Most patients are walking the day of surgery. The 30-day major complication rate at accredited centers is below one percent.

Diet progresses in stages over the first several weeks. Clear liquids begin in the hospital. Full liquids continue at home for the first one to two weeks. Pureed foods follow through week four. Soft foods are typically introduced around week four to six. A normal solid diet — modified in portion size — is generally tolerated by six to eight weeks. Our team provides specific dietary guidance at every stage. Protein intake is the top priority throughout recovery.

Return to desk work typically happens within one to two weeks. Physical activity beyond walking usually resumes at four to six weeks. Full exercise clearance is typically granted by eight weeks. We follow patients closely during this period.

What We Look For Before Recommending a Sleeve

The first thing I ask a patient who comes in requesting a sleeve is: do you have reflux? Not "have you ever had heartburn" — that's almost everyone. I mean: are you on a proton pump inhibitor? Do you wake up at night with acid? Have you had an endoscopy that showed esophagitis or Barrett's? Those answers change everything. If there is documented GERD, we are not doing a sleeve. I will recommend bypass, and I will explain exactly why. Patients who have already decided they want a sleeve sometimes push back on that. My job is to show them what the data say — that sleeve is likely to make their reflux significantly worse — and then let them make an informed decision.

We screen for GERD in every consultation. For patients with any reflux history, we require an upper endoscopy before surgery. More than half of my patients have a hiatal hernia — I don't base the procedure decision on the presence or size of the hernia alone. What drives the decision is the clinical picture: severe reflux, multiple reflux medications, Barrett's esophagus, intractable reflux, gastroparesis. Those patients get bypass. The hernia itself is largely a secondary finding.

BMI is the other major factor. For a patient with a BMI below 45 and no severe metabolic disease, sleeve is often the right first conversation. When BMI gets above 50, I want to make sure we are discussing SADI-S as a genuine option — not as a backup, but as potentially the better procedure upfront. The same applies to a patient with severe, poorly controlled type 2 diabetes. Sleeve will help. But bypass or SADI-S will likely do more, and we should have that conversation honestly before the patient commits to a procedure.

Patients who come in having already decided they want a sleeve — I take that seriously. I'm not going to recommend a procedure that isn't the best fit just because they came in expecting it. What I tell every patient is: come in with your preferred procedure in mind, and I will tell you honestly whether that preference makes sense for your anatomy and health history. If it does, great. If it doesn't, I'll explain why and what I would recommend instead.